The collaboration between the two companies aims to finish all necessary work needed to file for a first-in-human study by early 2019.
Helix BioPharma, an immuno-oncology company, has signed a collaboration agreement with ProMab Biotechnologies to develop novel antibody and chimeric antigen receptor T-cell (CAR-T) therapy for particular hematological malignancies, such as multiple myeloma, the company announced in a March 21, 2018 press release.
Helix had previously announced the signing of a binding letter of intent with ProMab to develop CAR-T for various hematological malignancies and solid tumors. The company has now signed its first scientific collaboration to co-develop a cell-based therapy for multiple myeloma (MM).
The MM co-development program will aim to complete all necessary work and intends to file for a first-in-human study by early 2019. Under the agreement, Helix will retain commercial rights for this CAR-T product in Canada and Europe and is currently in the process of reviewing the expansion criteria required for its European operations in Poland to facilitate commercialization.
Source: Helix BioPharma
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Pfizer Obtains Exclusive Rights to 3SBio’s Bispecific Antibody Targeting PD-1 and VEGF
August 1st 2025The licensing agreement between the two companies gives Pfizer the rights to develop, manufacture, and commercialize 3SBio’s bispecific antibody, SSGJ-707, which is in clinical trials for the treatment of a variety of cancers.